Methodology for eliciting an analgesic response in a living subject
AssigneeTrustees of Tufts College
InventorRichard M. Kream
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for eliciting an opioidal analgesia in a living subject using two classes of chemical compositions previously thought to have directly contradictory and physiologically antagonistic roles in the spinal analgesic process. The present methodology relies upon a concurrent administration of an opioid in marginal concentrations in combination with marginal doses of substance P or its related entities which function in a synergistic relationship and mechanism of action. The methodology relies upon a powerful potentiation and enhancement of an opioid-mediated response by the enhancing action of substance P to modulate or eliminate pain and other nociceptive responses, as well as inducing anesthesia.
Claims12
A method for enhancing an opioid analgesia within a living human subject, wherein said enhancing has a duration of at least 15 minutes, said method consisting essentially of the steps of:
- administering at least one pharmacologically active opioid selected from the group consisting of morphine and morphine-related opioid agonists to the living subject at a concentration which by itself is a pharmacologically marginal to ineffective picomolar concentration ranging from about 10 pmol/kg to about 10,000 pmol/kg of body weight, said administration being selected from the group consisting of subcutaneous and parenteral administrations;
- concurrently administering at least one enhancing agent selected from the group consisting of substance P and its pharmacologically active precursors and analogues to the living subject at a concentration which by itself is a pharmacologically ineffective picomolar concentration ranging from about 0.1 pmol/kg to about 100 pmol/kg of body weight and in a ratio ranging from about 1:10 to 1:100 with respect to said administered opioid concentration, said concurrent administration being selected from the group consisting of subcutaneous and parenteral administrations;
- and
- allowing said concurrently administered enhancing agent to interact with and enhance said administered opioid in-vivo such that an effective opioid analgesia results within the living subject.
A method for enhancing an opioid analgesia within a living human subject, wherein said enhancing has a duration of least 15 minutes, said method consisting essentially of the steps of:
- administering at least one pharmacologically active opioid selected from the group consisting of morphine and morphine-related opioid agonists to the living subject at a concentration which by itself is a pharmacologically marginal to ineffective picomolar concentration ranging from about 10 pmol to about 1000 pmol total opioid, said administration being selected from the group consisting of spinal and epidural administrations;
- concurrently administering at least one enhancing agent selected from the group consisting of substance P and its pharmacologically active precursors and analogues to the living subject at a concentration which by itself is a pharmacologically ineffective picomolar concentration ranging from about 1.0 pmol to about 1000 pmol total of enhancing agent and in a ratio ranging from about 1:10 to 1:100 with respect to said administered total opioid concentration, said concurrent administration being selected from the group consisting of spinal and epidural administrations;
- and
- allowing said concurrently administered enhancing agent to interact with and enhance said administered opioid in-vivo such that an effective opioid analgesia results within the living subject.
A method for enhancing an opioid analgesia within a living human subject, wherein said enhancing has a duration of at least 15 minutes, said method consisting essentially of the steps of:
- administering at least one pharmacologically active opioid selected from the group consisting of morphine and morphine-related opioid agonists to the living subject at a concentration which by itself is a pharmacologically marginal to ineffective picomolar concentration ranging from about 10 pmol to about 1000 pmol total opioid, said administration being selected from the group consisting of spinal and epidural administrations;
- concurrently administering at least one enhancing agent selected from the group consisting of substance P and its pharmacologically active precursors and analogues to the living subject at a concentration which by itself is a pharmacologically ineffective picomolar concentration ranging from about 0.1 pmol/kg to about 100 pmol/kg of body weight and in a ratio ranging from about 1:10 to 1:100 with respect to said administered opioid concentration, said concurrent administration being selected from the group consisting of subcutaneous and parenteral administrations;
- and
- allowing said concurrently administered enhancing agent to interact with and enhance said administered opioid in-vivo such that an effective opioid analgesia results within the living subject.
Dependencies are inferred from the claim text.